| Withdrawn | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PT Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH), Follicular T-cell Lymphoma (FTCL) | Phase 2 / Phase 3 | 2019-11-15 |
| Withdrawn | BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis Venous Thromboses | — | 2018-09-01 |
| Completed | The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Anta Hepatic Impairment | Phase 1 | 2017-11-16 |
| Completed | A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Bleeding | Phase 2 | 2017-08-28 |
| Completed | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa Bleeding | Phase 1 | 2017-02-26 |
| Completed | A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations Healthy | Phase 1 | 2015-09-01 |
| Terminated | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing Bleeding | Phase 2 | 2015-08-06 |
| Completed | A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation E Bleeding | Phase 3 | 2014-05-01 |
| Completed | A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Bleeding | Phase 3 | 2014-03-01 |
| Completed | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood T Healthy Volunteers | Phase 2 | 2012-12-01 |
| Completed | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood T Healthy Volunteers | Phase 2 | 2012-12-01 |
| Completed | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood T Healthy Volunteers | Phase 2 | 2012-12-01 |
| Completed | Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood T Healthy Volunteers | Phase 2 | 2012-12-01 |
| Completed | Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote Healthy | Phase 1 | 2012-06-01 |
| Completed | Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study) Venous Thromboembolism (VTE) | Phase 3 | 2012-03-01 |
| Completed | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or At Atrial Fibrillation, Atrial Flutter | Phase 2 | 2010-09-01 |
| Terminated | Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairm Renal Impairment | Phase 1 | 2009-09-01 |
| Completed | A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With M Renal Impairment | Phase 1 | 2009-07-31 |
| Completed | A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent Percutaneous Coronary Intervention | Phase 2 | 2008-12-01 |
| Completed | Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared t Atrial Fibrillation | Phase 2 | 2008-10-01 |
| Terminated | Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI Myocardial Infarction | Phase 2 | 2007-11-01 |
| Completed | A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers Healthy Subjects | Phase 1 | 2007-09-01 |
| Completed | An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy M Health Volunteers | Phase 1 | 2007-09-01 |
| Completed | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) Thromboembolism | Phase 2 | 2006-05-01 |